在摩根士丹利近日举办的会议上，礼来公司高管释放重磅信号：该公司目前在口服减肥治疗领域的新患市场份额，已稳稳突破30%大关。这一数据，无疑为竞争日趋白热化的减肥药赛道，投下了一枚深水炸弹。礼来方面并未止步于此，其表述透露出对现有市场地位的自信，以及对未来持续扩张的笃定。分析师普遍认为，这一份额的取得，标志着礼来在口服减肥药物这一细分战场上，已经构建起不容小觑的护城河。
在摩根士丹利近日举办的会议上，礼来公司高管释放重磅信号：该公司目前在口服减肥治疗领域的新患市场份额，已稳稳突破30%大关。这一数据，无疑为竞争日趋白热化的减肥药赛道，投下了一枚深水炸弹。礼来方面并未止步于此，其表述透露出对现有市场地位的自信，以及对未来持续扩张的笃定。分析师普遍认为，这一份额的取得，标志着礼来在口服减肥药物这一细分战场上，已经构建起不容小觑的护城河。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.